14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
FLZH vs BIAF: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, bioAffinity Technologies, Inc. (BIAF) is the stronger overall head-to-head candidate over FLZH (FLZH) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FLZH carries a Unified Composite Score of 48.8/100 (HOLD) at $0.10 (N/M Forward P/E, N/A operating margin), whereas BIAF carries 48.0/100 (HOLD) at $1.65 (N/M Forward P/E, -246.1% operating margin).
Composite vs. Pillar Nuance: While FLZH currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. BIAF 48.0/100 HOLD), BIAF captures the overall institutional head-to-head verdict (7–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-246.1% vs. N/A operating margin) and revenue trajectory (-26.0% vs. N/A YoY).
Technical & Structure Timing Caution: FLZH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile BIAF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FLZH vs BIAF. Trailing 12-month operating profitability (FLZH N/A vs BIAF -246.1%) and valuation multiples (FLZH N/M vs BIAF N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Diagnostics & Research value chain with $3.3M market capitalization and -246.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FLZH vs BIAF Key Questions & Quantitative Answers
As of Nov 20, 2026, bioAffinity Technologies, Inc. (BIAF) is the stronger overall head-to-head candidate over FLZH (FLZH) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FLZH carries a Unified Composite Score of 48.8/100 (HOLD) at $0.10 (N/M Forward P/E, N/A operating margin), whereas BIAF carries 48.0/100 (HOLD) at $1.65 (N/M Forward P/E, -246.1% operating margin). Composite vs. Pillar Nuance: While FLZH currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. BIAF 48.0/100 HOLD), BIAF captures the overall institutional head-to-head verdict (7–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-246.1% vs. N/A operating margin) and revenue trajectory (-26.0% vs. N/A YoY). Technical & Structure Timing Caution: FLZH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile BIAF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BIAF leads the Growth & Scale pillar: FLZH posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BIAF at -26.0% YoY revenue growth and +0.0% YoY earnings growth on $5.5M TTM revenue (27.0% gross margin, -246.1% operating margin). On trailing 12-month operating scale, FLZH generates N/A in USD-normalized revenue versus $5.5M for BIAF. In operating R&D and SG&A reinvestment, FLZH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BIAF.
BIAF screens cheaper on headline valuation multiples. FLZH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BIAF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FLZH (N/A ROE) versus BIAF (-240.5% ROE) capital efficiency.
In options market volatility and institutional positioning, FLZH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.90β · 329% Vol realized risk). By comparison, BIAF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.62β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.